Treatment with Azacitidine of Patients with End-Stage β-Thalassemia

Abstract excerpt

Regular erythrocyte transfusions form the cornerstone of treatment for patients with severe β-thalassemia. Despite the use of iron-chelation therapy, fatal iron overload develops in many patients, even when they are under supervision and taking part in studies designed to test the effectiveness of intense chelation1,2. Another potential consequence of long-term transfusions is the development of antierythrocyte...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Erythrocyte Function and Pathophysiology
• Share to Hemoglobinopathies and Related Disorders
• Share to Iron Metabolism and Disorders